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A 60-year-old man with lung adenocarcinoma, judgedinoperable, underwent perfusion computed tomography
(pCT) scan before and after 3 and 6 months of conventional
and antiangiogenic chemotherapy (Paclitaxel 175 mg/mq and
Bevacizumab 7.5 mg/kg). The treatment started immediately
after the first pCT examination and was repeated every 21
days for 6 months (Figures 1 and 2).
pCT parameters adopted by applying dedicated perfu-
sional software were blood flow, blood volume, time to peak,
and permeability.1
Objective response in clinical practice is evaluated by
RECIST, measuring only the maximal axial diameter of the
lesions.
Changes, as demonstrated in this case, suggest that pCT
should be considered as part of the response evaluation with
antiangiogenesis agents.
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FIGURE 1. CT sagittal image shows that the maximal diameter of the lesion was 19 mm (A) before starting therapy (January
2010). After 3 months, the lesion showed a stable diameter (B); after 6 months, there was a decrease in morphology (C).
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FIGURE 2. pCT sagittal image of the same patient shows an inhomogeneous vascularity (A), measured by color-coded maps
of perfusional parameters (from blue to red), before starting therapy. After 3 months, there was a decrease of vascularity (B),
whereas after 6 months, there was a decrease in morphology with a loss in vascularity (C).
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